IBDEI219 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32449,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32449,1,3,0)
 ;;=3^Retinal Artery Branch Occlusion,OU
 ;;^UTILITY(U,$J,358.3,32449,1,4,0)
 ;;=4^H34.233
 ;;^UTILITY(U,$J,358.3,32449,2)
 ;;=^5005566
 ;;^UTILITY(U,$J,358.3,32450,0)
 ;;=H34.8310^^128^1661^4
 ;;^UTILITY(U,$J,358.3,32450,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32450,1,3,0)
 ;;=3^BRVO,OD w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,32450,1,4,0)
 ;;=4^H34.8310
 ;;^UTILITY(U,$J,358.3,32450,2)
 ;;=^5138488
 ;;^UTILITY(U,$J,358.3,32451,0)
 ;;=H34.8311^^128^1661^5
 ;;^UTILITY(U,$J,358.3,32451,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32451,1,3,0)
 ;;=3^BRVO,OD w/ Retinal Neovascularization
 ;;^UTILITY(U,$J,358.3,32451,1,4,0)
 ;;=4^H34.8311
 ;;^UTILITY(U,$J,358.3,32451,2)
 ;;=^5138489
 ;;^UTILITY(U,$J,358.3,32452,0)
 ;;=H34.8312^^128^1661^6
 ;;^UTILITY(U,$J,358.3,32452,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32452,1,3,0)
 ;;=3^BRVO,OD,Stable
 ;;^UTILITY(U,$J,358.3,32452,1,4,0)
 ;;=4^H34.8312
 ;;^UTILITY(U,$J,358.3,32452,2)
 ;;=^5138490
 ;;^UTILITY(U,$J,358.3,32453,0)
 ;;=H34.8320^^128^1661^7
 ;;^UTILITY(U,$J,358.3,32453,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32453,1,3,0)
 ;;=3^BRVO,OS w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,32453,1,4,0)
 ;;=4^H34.8320
 ;;^UTILITY(U,$J,358.3,32453,2)
 ;;=^5138491
 ;;^UTILITY(U,$J,358.3,32454,0)
 ;;=H34.8321^^128^1661^8
 ;;^UTILITY(U,$J,358.3,32454,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32454,1,3,0)
 ;;=3^BRVO,OS w/ Retinal Neovascularization
 ;;^UTILITY(U,$J,358.3,32454,1,4,0)
 ;;=4^H34.8321
 ;;^UTILITY(U,$J,358.3,32454,2)
 ;;=^5138492
 ;;^UTILITY(U,$J,358.3,32455,0)
 ;;=H34.8322^^128^1661^9
 ;;^UTILITY(U,$J,358.3,32455,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32455,1,3,0)
 ;;=3^BRVO,OS,Stable
 ;;^UTILITY(U,$J,358.3,32455,1,4,0)
 ;;=4^H34.8322
 ;;^UTILITY(U,$J,358.3,32455,2)
 ;;=^5138493
 ;;^UTILITY(U,$J,358.3,32456,0)
 ;;=H34.8110^^128^1661^10
 ;;^UTILITY(U,$J,358.3,32456,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32456,1,3,0)
 ;;=3^CRVO,OD w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,32456,1,4,0)
 ;;=4^H34.8110
 ;;^UTILITY(U,$J,358.3,32456,2)
 ;;=^5138476
 ;;^UTILITY(U,$J,358.3,32457,0)
 ;;=H34.8111^^128^1661^11
 ;;^UTILITY(U,$J,358.3,32457,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32457,1,3,0)
 ;;=3^CRVO,OD w/ Retinal Neovascularization
 ;;^UTILITY(U,$J,358.3,32457,1,4,0)
 ;;=4^H34.8111
 ;;^UTILITY(U,$J,358.3,32457,2)
 ;;=^5138477
 ;;^UTILITY(U,$J,358.3,32458,0)
 ;;=H34.8112^^128^1661^12
 ;;^UTILITY(U,$J,358.3,32458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32458,1,3,0)
 ;;=3^CRVO,OD,Stable
 ;;^UTILITY(U,$J,358.3,32458,1,4,0)
 ;;=4^H34.8112
 ;;^UTILITY(U,$J,358.3,32458,2)
 ;;=^5138478
 ;;^UTILITY(U,$J,358.3,32459,0)
 ;;=H34.8120^^128^1661^13
 ;;^UTILITY(U,$J,358.3,32459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32459,1,3,0)
 ;;=3^CRVO,OS w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,32459,1,4,0)
 ;;=4^H34.8120
 ;;^UTILITY(U,$J,358.3,32459,2)
 ;;=^5138479
 ;;^UTILITY(U,$J,358.3,32460,0)
 ;;=H34.8121^^128^1661^14
 ;;^UTILITY(U,$J,358.3,32460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32460,1,3,0)
 ;;=3^CRVO,OS w/ Retinal Neovascularization
 ;;^UTILITY(U,$J,358.3,32460,1,4,0)
 ;;=4^H34.8121
 ;;^UTILITY(U,$J,358.3,32460,2)
 ;;=^5138480
 ;;^UTILITY(U,$J,358.3,32461,0)
 ;;=H34.8122^^128^1661^15
 ;;^UTILITY(U,$J,358.3,32461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32461,1,3,0)
 ;;=3^CRVO,OS,Stable
